MEDXF News and Press, Medexus Pharmaceuticals Inc From 11/13/22

Medexus Pharmaceuticals Inc. (MEDXF) Q2 2023 Earnings Conference Call November 9, 2022 08:00 ET Company Participants Victoria Rutherford - Investor Relations, Adelaide Capital Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Office...

Medexus Pharmaceuticals press release ( OTCQX:MEDXF ): Q2 Revenue of C$27.7M (+55% Y/Y). Adjusted Net Loss, of -C$2.8M, a year-over-year improvement of $3.3M. Cash and cash equivalents of C$9.6M (with C$10.1M of total available liquidity) at end of fiscal Q2 2023. Fo...

Results reflect strong growth across all leading prescription products, including IXINITY, Rupall, and Gleolan Management to host conference call at 8:00 AM Eastern Time on Wednesday, November 9, 2022 TORONTO and CHICAGO, Nov. 08, 2022 (GLOBE NEWSWIRE) --  Medexus P...

TORONTO and CHICAGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, November 9, 2022 to discuss Medexus’s results for its second quar...

Medexus Pharmaceuticals ( OTCQX:MEDXF ) expects revenue between $27M and $27.5M for fiscal Q2 2023 vs. consensus estimate of $23.72M. This will represent the strongest fiscal quarter in the company's history, and an increase of at least 51% Y/Y and at least 17% sequentiall...

TORONTO and CHICAGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s ...

Medexus’s borrowing capacity under its revolving credit facility increases by US$5.0 million, from US$20.0 million to US$25.0 million Transaction strengthens Medexus’s balance sheet, providing additional operating liquidity TORONTO and CHIC...

FDA requests further information from medac, continues to engage with treosulfan NDA Medexus continues to focus on maintaining momentum and growth in its North American on-market portfolio, and is now recognizing 100% of Gleolan U.S. net sales as of September Medexus to host li...

All director nominees reelected for the coming year All other proposals also approved by shareholders TORONTO and CHICAGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of sh...

Medexus Pharmaceuticals Inc. (MEDXF) Q1 2023 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d’Entremont - CEO Marcel Konrad - CFO Conference Call Participants Justin Keywoo...